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Summary
Lysinuric protein intolerance (LPI) is a rare autosomal
recessive defect of cationic amino acid transport caused
by mutations in the SLC7A7 gene. We report the ge-
nomic structure of the gene and the results of the mu-
tational analysis in Italian, Tunisian, and Japanese pa-
tients. The SLC7A7 gene consists of 10 exons; sequences
of all of the exon-intron boundaries are reported here.
All of the mutant alleles were characterized and eight
novel mutations were detected, including two missense
mutations, 242ArC (M1L) and 1399CrA (S386R); a
nonsense mutation 967GrA (W242X); two splice mu-
tations IVS3 +1GrA and IVS6 +1GrT; a single-base
insertion, 786insT; and two 4-bp deletions, 455del-
CTCT and 1425delTTCT. In addition, a previously re-
ported mutation, 1625insATCA, was found in one pa-
tient. It is noteworthy that 242ArC causes the change
of Met1 to Leu, a rare mutational event previously found
in a few inherited conditions. We failed to establish a
genotype/phenotype correlation. In fact, both intrafam-
ilial and interfamilial phenotypic variability were ob-
served in homozygotes for the same mutation. The
DNA-based tests are now easily accessible for molecular
diagnosis, genetic counseling, and prenatal diagnosis of
LPI.
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Introduction
Lysinuric protein intolerance (LPI; MIM 222700) is a
rare autosomal recessive disease that is relatively com-
mon in Finland (Simell 1995) and Italy (Incerti et al.
1993). Clinical findings of LPI include vomiting, diar-
rhea, failure to thrive, episodes of coma, hepatosplen-
omegaly, and osteoporosis. A life-threatening lung in-
volvement, mainly alveolar proteinosis, and severe renal
involvement have also been reported (Parenti et al. 1995;
Simell 1995; Santamaria et al. 1996a). Metabolic de-
rangement is characterized by reduced intestinal ab-
sorption of cationic amino acid (lysine, ornithine, ar-
ginine [CAA]), increased renal excretion of CAA, orotic
aciduria, and dysfunction of urea cycle leading to hy-
perammonemia. The disease is considered relatively be-
nign when appropriately treated with citrulline supple-
mentation and a low-protein diet, but this treatmentmay
be insufficient to prevent severe complications. LPI is
caused by a defective transport of CAA at the basolateral
membrane of the epithelial cells of intestine and kidney
(Simell 1995). This transport is mediated by systems y
and yL, the former exerted by human CAA transporters
1, 2, and 4 (CAT1-4) (Palacin et al. 1998). The latter is
induced by heterodimers consisting of the 4F2 heavy
chain (4F2hc) and the light chain of either the solute
carrier family 7A, member 6 (SLC7A6) or member 7
(SLC7A7) (Torrents et al. 1998, 1999). Previous studies
excluded human CAT1-4 and 4F2hc as candidate genes
of LPI. Recently, the LPI gene SLC7A7, located on chro-
mosome 14q11.2, has been identified (Borsani et al.
1999; Torrents et al. 1999). SLC7A7 protein forms an
∼135-kDa disulfide bond–dependent heterodimer with
4F2hc in oocytes, which, on reduction, results in two
peptides of ∼85 kDa (4F2hc) and ∼40 kDa (SLC7A7).
A hydrophobicity plot of SLC7A7 predicts 12 trans-
membrane (TM) domains with both C- and N-terminal
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segments in the cytoplasm. Five mutations of the
SLC7A7 gene were reported in Italian, Finnish, and
Spanish patients with LPI (Borsani et al. 1999; Torrents
et al. 1999). A splice-acceptor mutation (IVS5-2ArT,
previously reported as 1136-2ArT) accounts for the
founder LPI allele in Finland (Borsani et al. 1999; Tor-
rents et al. 1999). In the same study, the 1625insATCA
mutation was found in homozygosity in three unrelated
Italian pedigrees, all originating from a restricted geo-
graphical area and all sharing a common haplotype
linked to the LPI locus. Surprisingly, a different muta-
tion, 197-740del, was found in homozygosity in another
patient originating from the same restricted area. This
result suggested a possible mutational heterogeneity of
the SLC7A7 gene in Italian patients with LPI.
In the present study, we report the structure of the
human SLC7A7 gene, which enables a rapid screening
of mutations in patients with LPI. In addition, we report
the identification of eight novel mutations, definitely in-
dicating an unusually high degree of mutational heter-
ogeneity of LPI, at least in Italy.
Subjects, Material, and Methods
Patients
Fourteen patients with LPI from 11 independent fam-
ilies were investigated for the presence of mutations of
the SLC7A7 gene. Clinical findings of the Italian and
Tunisian patients were reported elsewhere (Parini et al.
1991; Di Rocco et al. 1993; Incerti et al. 1993; Candito
et al. 1994; Parenti et al. 1995; Santamaria et al. 1996a;
Parenti et al. 1998).
The Japanese patient presented with hepatosplen-
omegaly at age 3 mo. Hyperammonemia and seizures
were reported at age 18 mo. The diagnosis of LPI was
defined at age 10 years. At the moment, mental devel-
opment is normal, and no complications have been ob-
served.
Nine families originated from southern Italy, one from
Tunisia, and one from Japan. Six of the 14 patients (pa-
tients 1A, 1B, 2, 3, 9A, 9B, and 11) were born to con-
sanguineous parents. DNA samples from parents and
unaffected sibs, where available, were also investigated
to confirm the correct segregation of each mutation.
Structure of the SLC7A7 Gene
The human genomic PAC library RPCI-5 was screened
by use of two sets of primers located at the 5′ end (for-
ward, 5′-GGAGATCTCACTGCTTAACGG-3′, and re-
verse, 5′-AGGCGGCTGGCAGCATAAG-3′) and at the
3′ end (forward, 5′-AAATTGGAGCATTGTGGGC-3′,
and reverse, 5′-AGCCTCACTTCCTTTGGAGG-3′) of
SLC7A7 cDNA, and two positive clones were identified.
Automated sequencing by means of an Applied Bios-
ystem ABI 377 fluorescent sequencer of PAC DNA and
PCR-amplified genomic DNA was done by using gene-
specific oligonucleotide primers with ABI PRISM Big
Dye Terminator Cycle Sequencing Ready Reaction kit
(PE Biosystems).
Genomic DNA Preparation and Amplification of the
SLC7A7 Gene
Genomic DNA was extracted by standard methods
from peripheral blood samples of members of all fam-
ilies, cultured skin fibroblasts, and Epstein-Barr vi-
rus–transformed lymphocytes (Sambrook et al. 1989).
Exons of the SLC7A7 gene were amplified by PCR
(Therm Cycler 480; PE Biosystems) with primers de-
signed for exons 1–10. Exon 2 was amplified in two
pieces (2a and 2b) by use of two sets of primers.
PCR reactions were done in a total volume of 25 ml,
which contained 50 ng of template DNA, 1#AmpliTaq
reaction buffer (PE Biosystems), 250 mM of each nucle-
otide, 50 ng of each primer, and 0.5 U of AmpliTaq
DNA polymerase (PE Biosystems). The reactions were
done for 39 cycles, with denaturation at 94C for 1 min,
annealing at 50C–60C for 1 min, and extension at
72C for 1 min. In the first cycle, denaturation was done
for 7 min, and, in the final cycle, the extension lasted 7
min.
Southern Hybridization
Genomic DNA from 14 patients with LPI and two
controls were digested with EcoRI and PstI restriction
enzymes, according to the manufacturer’s recommen-
dations. After electrophoresis in a 1% agarose gel, the
digested DNAs were transferred onto a Hybond-N
membrane (Amersham). The membrane was hybridized
at 65C in a buffer containing 6# SSC, 1#Denhardt’s
solution, 0.5% SDS, 0.2 mg/ml sonicated herring-sperm
DNA, and 32PdCTP-labeled full-length SLC7A7 cDNA
probe.
SSCP Analysis and Direct Sequencing
For the SSCP analysis, 0.4 ml of 32PdCTP (3,000 Ci/
mmol) were added to the PCR-mix reaction. Primers
used for PCR-SSCP are listed in table 2, and the con-
ditions are the same as those described for genomicDNA
amplifications. SSCP was done on a 6% polyacrylamide
nondenaturing gel. Direct sequencing was done on PCR
products showing SSCP band shifts. Both strands of the
PCR products were sequenced by an automated system
(ABI PRISM 377).
Restriction Enzyme Digestion of PCR Products
For those mutations (242ArC, 967GrA, 1399CrA)
introducing or abolishing the recognition sequence of a
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Table 1
Exon-Intron Boundaries and Sizes of Exons of the SLC7A7 Gene
Exon 3′ Splice Sitea 5′ Splice Sitea Exon sizeb
1 ) CAAGGAgtgagtgtgc ?
2 ttccttaaagGGCAAT GCATCTgtaagcgggg 540
3 tttctttcagGTCTCT GCCAGGgttaagaaat 125
4 tgggttccagGAGCCT TGAGAGgtaggtactg 144
5 ttggctgtagGAACCT GCTGTGgtaaaggatt 123
6 tttcccttagACTTTT TTCTAGgtaagagtgg 103
7 cctaacatagGCTTTT TTCAATgtaagtgaac 97
8 acgcttacagGGTATC CTCAAGgtaaggcaac 183
9 gtgcccttagCTCAGC TCGTGGgtaagccgtg 99
10 ctctttgtagGGTCTG ) ?
a Intron sequences are shown in lowercase letters. Exon sequences
are shown in uppercase letters.
b ? = Exon size unknown.
restriction enzyme, the specific PCR products were di-
gested with the requested restriction enzyme (NcoI,
BsmAI,HinfI) following the manufacturer’s instructions
(New England Biolabs). Digests were analyzed on a 2%
Separide Gel Matrix (Gibco BRL).
Results
Structure of the SLC7A7 Gene
The RPCI-5 PAC library was screened by use of two
sets of primers located at the 5′ and 3′ ends of SLC7A7
cDNA, and two clones were identified. One of them,
PAC clone 830D3, contains the entire gene. The location
and sequence of all exon-intron boundaries (table 1)
were determined by direct sequencing of either the PAC
clone or the PCR products obtained from amplification
of genomic DNA with cDNA-derived oligonucleotide
primers.
The SLC7A7 gene was shown to be organized in 10
exons with sizes in the range of 97–540 bp. All of the
exon-intron junctions agree with the gt–ag consensus
sequence. Primers for the amplification of all SLC7A7
exons were designed in the intronic flanking sequences
and are reported in table 2. The codon for the trans-
lation-initiator methionine (Met1) is located in exon 2
at position 242, whereas the termination codon, TAA,
is located at position 1775 in exon 10.
Analysis of the SLC7A7 Gene in Patients with LPI
Southern blot analysis of genomic DNA revealed no
detectable differences in the patients with LPI vis-a`-vis
the controls, excluding major rearrangements (data not
shown). The search for mutations was then done by
SSCP analysis of each of the 10 exons, including the
exon-intron boundaries, in 14 patients with LPI and two
controls. Abnormal SSCP conformers were detected for
exons 2, 3, 4, 6, 8, and 9. By direct sequencing, we found
eight novel mutations and one previously reported mu-
tation (table 3). All patients were homozygous for a
specific mutation, except the Japanese patient.
A missense mutation at codon 1 (M1L).—On both al-
leles of two affected brothers, patients 1A and 1B born
to consanguineous parents, we identified a 242ArC
transversion that caused a methionine-to-leucine change
at codon 1 in exon 2 (M1L). An NcoI site is destroyed
by this mutation. By NcoI digestion of exon 2, we con-
firmed that these patients are homozygous for this mu-
tation and that the parents and the unaffected sister are
heterozygous.
A missense mutation at codon 386 (S386R).—In two
independent patients (2 and 3), both born to first-cousin
parents, we identified a 1399CrA transversion that
changed a serine to arginine at codon 386 (S386R) in
exon 8. Both patients are homozygous for this mutation,
which introduces a new HinfI site in exon 8. In both
patients, sequencing of the remainder of the coding re-
gion and the exon-intron boundaries of the gene did not
detect other mutations. ByHinfI digestion of exon 8, we
confirmed that patients 2 and 3 are homozygous for the
S386R mutation and that all of their parents are het-
erozygous. Two unaffected sisters of patient 2 were het-
erozygous and homozygous for the wild-type allele, re-
spectively. This mutation was not detected in HinfI
digests of amplified exon 8 from 54 unrelated control
DNAs (data not shown).
A nonsense mutation at codon 242 (W242X).—In two
independent patients (4 and 5), a 967GrA transition
creates a termination codon TGA (W242X) in exon 4.
Both patients are homozygous for this mutation, which
introduces a new BsmAI site in exon 4. By BsmAI di-
gestion of exon 4, we confirmed that patients 4 and 5
are homozygous for the 967GrA mutation and all of
their parents are heterozygous. An unaffected brother of
patient 4 was heterozygous.
A single-base insertion in exon 3 (786insT).—In two
affected brothers, patients 6A and 6B, a T insertion in
exon 3, 786insT, causes a frameshift and introduces a
termination codon (TAA) at position 812. Both patients
are homozygous for this mutation. Direct sequencing of
exon 3 revealed a carrier status of the parents for this
mutation.
A 4-bp deletion in exon 2 (455delCTCT).—Patient 7
was homozygous for a 4-bp deletion in exon 2,
455delCTCT, which causes a frameshift and introduces
a termination codon (TAA) at position 743. Direct se-
quencing of exon 2 revealed that the parents and an
unaffected brother are heterozygous for this mutation.
A 4-bp deletion in exon 8 (1425delTTCT).—A 4-bp
deletion in exon 8, 1425delTTCT, was found in ho-
mozygosity in patient 8 and in two affected Tunisian
brothers (9A and 9B). This mutation causes a frameshift
that abolishes the termination codon at position 1775,
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Table 2






1 5′-ACTGCTGGCTGGGAAGGAG-3′ 5′-gagggttagcaaggtaagtgg-3′ 158
2a 5′-gccaaccacctaatcgtatag-3′ 5′-CAGATTTCTTAATGGTGGTGCCC-3′ 384
2b 5′-GCTGTCGGGGGCCTCTTCTCCG-3′ 5′-tagcctcctaccccagccc-3′ 295
3 5′-gagtctaaggccctagggtgg-3′ 5′-ctgcaggctgtttcctcatcc-3′ 343
4 5′-tgtcagtcctttacttgaccatc-3′ 5′-tatggaaagttggtggtgcag-3′ 252
5 5′-gagatagggatatgactgtggg-3′ 5′-cagtaccccacaagacaccc-3′ 227
6 5′-agatcctgctaatgactcttcc-3′ 5′-gttctgtccactgcatagccc-3′ 200
7 5′-ccaattttctcagcttctcc-3′ 5′-cgcaatctggctttcagtctc-3′ 173
8 5′-aaggccctgagaagagctg-3′ 5′-ttcaggtggagcagaggtagg-3′ 225
9 5′-gaatcctgagttgtccactcc-3′ 5′-agctctgcaatagctgagcgg-3′ 270
10 5′-tgagttccattcagtgacacctg-3′ 5′-AAATTGGAGCATTGTGGGC-3′ 500
NOTE.—Intron sequences are shown in lowercase letters. Exon sequences are shown in uppercase letters.
introducing a new TGA at position 1790. By SSCP anal-
ysis of exon 8, we found all parents were heterozygous
for this mutation as was an unaffected sister of patient
8.
Two splice mutations at IVS3 1GrA and IVS6
1GrT.—In patient 10, from Japan, two splice muta-
tions were found in heterozygosis. The first one, inher-
ited from the mother, is a GrA transition at the donor
site of intron 3. The second one, inherited from the fa-
ther, is a GrT transversion at the donor site of intron
6. The sequences of the remainder of the coding region
and the exon-intron boundaries of the gene were iden-
tical to the wild type. Two unaffected sibs were hetero-
zygous for IVS31GrA and IVS61GrT, respectively.
1625insATCA mutation.—In patient 11, born to first-
cousin parents, we found homozygosity for 1625ins-
ATCA, a mutation previously reported (Borsani et al.
1999). This mutation results in a frameshift that disrupts
the reading frame at codon 462 and introduces a trans-
lation termination codon (TGA) 13 bp downstream. Di-
rect sequencing of exon 9 from genomic DNA of the
parents revealed their carrier status for this mutation.
Discussion
The present study provides the complete structure of
the LPI gene, SLC7A7, including sequences and PCR
conditions, to enable mutational analysis of all 10 exons
of the gene. Southern blot analysis of patients’ genomic
DNA did not reveal gross gene rearrangements as pre-
viously observed in patient 16. We then searched for
mutations of the SLC7A7 gene by using SSCP analysis
in 1 Japanese, 2 Tunisian, and 11 Italian patients, rep-
resenting 18 affected independent alleles. This study led
to the identification of eight novel mutations and an
already-known mutation. All the affected alleles were
identified, and each patient was homozygous for a spe-
cific mutation, except the Japanese patient (table 3). The
segregation of each mutation in the pedigree was co-
herent with the recessive mode of inheritance of the
disease.
Characteristics of the Mutations
The missenseM1L changes the first methionine (Met1)
to leucine. Mutations of the translation-initiator ATG
(Met1) have rarely been observed in inherited diseases.
However, such a mutation was recently found in the
RHAG gene in patients affected by Rhmod syndrome
(Huang et al. 1999), in which use of alternative ATGs
in the RHAG mRNA was allowed by some in-frame
ATGs sharing significant homology with Kozak’s con-
sensus sequence (Kozak 1987). In our case, the sequence
context of the subsequently available ATG (Met50,
GGGAACATGA) does not conform to Kozak’s consen-
sus (CCA[G/A]CCATGG). If we used this ATG, the mu-
tated protein would lack the first 49 amino acid residues
corresponding to the intracellular N-terminus and part
of the first TM domain. In addition, the N-terminus
truncation would affect the insertion of the protein into
the lipid bilayer (Singer 1990). A better Kozak consensus
is found for the following ATG (Met143), but more dra-
matic alteration of the protein should be expected.
The missense mutation S386R was found in two in-
dependent patients originating from the same geographic
area (Calabria). We do not have formal proof that
S386R is a disease-causing mutation. However, its caus-
ative effect is strongly supported by the following: (1)
absence of other mutations within the coding region and
the exon-intron boundaries of the SLC7A7 gene in both
patients; (2) absence of this mutation in 108 control
alleles, which excludes it as a polymorphic change; (3)
the mutation coherently segregates with the phenotype;
and (4) the serine residue at position 386 is conserved
in the mouse ortholog (myLAT1) and in homologous
proteins, such as hyLAT2, hLAT1, and IU12 (Torrents
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Table 3
Mutations of the SLC7A7 Gene in Italian, Tunisian, and Japanese Patients with LPI
PATIENTa ETHNICITY
MUTATION
SOURCE OF DATAAllele 1 Allele 2
1A Italian (Puglia) M1L M1L Present study
1B Italian (Puglia) M1L M1L Present study
2 Italian (Calabria) S386R S386R Present study
3 Italian (Calabria) S386R S386R Present study
4 Italian (Calabria) W242X W242X Present study
5 Italian (Lazio) W242X W242X Present study
6A Italian (Sicilia) 786insT 786insT Present study
6B Italian (Sicilia) 786insT 786insT Present study
7 Italian (Molise) 455delCTCT 455delCTCT Present study
8 Italian (Campania) 1425delTTCT 1425delTTCT Present study
9A Tunisian 1425delTTCT 1425delTTCT Present study
9B Tunisian 1425delTTCT 1425delTTCT Present study
10 Japanese IVS3 1GrA IVS6 1GrT Present study
11 Italian (Campania) 1625insATCA 1625insATCA Present study
12 Italian (Campania) 1625insATCA 1625insATCA III-2, F2 in Borsani et al. (1999)
13 Italian (Campania) 1625insATCA 1625insATCA III-3, F3 in Borsani et al. (1999)
14C Italian (Campania) 1625insATCA 1625insATCA III-6, F4 in Borsani et al. (1999)
15C Italian (Campania) 1625insATCA 1625insATCA IV-2, F4 in Borsani et al. (1999)
16 Italian (Campania) 197-740delb 197-740delb IV-2, F1 in Borsani et al. (1999)
a “A” and “B” indicate that the patients are siblings; “C” indicates that the patients are consan-
guineous.
b Previously reported as 197D543 mutation by Borsani et al. (1999)
et al. 1998; Pfeiffer et al. 1999). Linkage analysis with
markers of the LPI locus showed that the two patients
carry different haplotypes (Lauteala et al. 1998). This
suggests that the same mutation arose independently in
the two pedigrees. Alternatively, multiple recombina-
tional events on a common ancestral allele would have
been required.
The nonsense mutation W242X in exon 4 was found
in two independent patients originating from different
geographic areas (Calabria and Lazio). The linkage anal-
ysis with markers of the LPI locus showed different hap-
lotypes in the two patients, thus suggesting independent
mutational events. The predicted mutated protein would
lack 7 of the 12 TM domains and the intracellular C-
terminus, which should yield a nonfunctional product.
The splice mutations found in the Japanese patient,
IVS3 1GrA and IVS6 1GrT, disrupt the GT rule
of the donor splice sites of introns 3 and 6, respectively.
Unfortunately, none of the patient’s cell lines were avail-
able for mRNA studies. Nevertheless, the kind of mu-
tations, in addition to the segregation data and the ab-
sence of changes in the coding region and in the other
exon-intron boundaries, all appear to be conclusive for
a disease-causing role.
The 786insT mutation causes a frameshift and a pre-
mature termination of translation at position 812. The
predicted mutated protein would be severely altered be-
cause of the lack of the last 9 TM domains and the
intracellular C-terminus.
Even more dramatic is the effect of the 455delCTCT
mutation. The frameshift introduces a premature ter-
mination codon (TAA) in the reading frame at position
743. The predicted mutated protein lacks all of the TM
domains and the intracellular C-terminus.
The 1425delTTCT mutation causes a frameshift that
abolishes the wild-type termination codon, introducing
a new one (TGA) at position 1790, 15 bp downstream
of the former. The resulting protein would differ from
the wild-type sequence in the last 116 amino acid resi-
dues, with a gain of 5 residues at the intracellular C-
terminus stretch. The hydrophobicity plot of the mu-
tated protein predicts a dramatic change of the last four
TM domains of the wild-type protein, with loss of an
entire domain and shortening of the C-terminus stretch.
Interestingly, this mutation was found in both Italian
and Tunisian patients. Haplotype analysis might help us
to understand if migrations within the Mediterranean
basin contributed to the spread of this mutation, as has
been observed for several other inherited diseases.
The 1625insATCA mutation was found in patient 11,
who originates from the same geographic area (Cam-
pania) as four other patients already reported (12, 13,
14C, and 15C in table 3). These four patients are ho-
mozygous for the same mutation, and the affected allele
might descend from a common ancestor, as suggested
by pedigree analysis and haplotypes linked to the LPI
locus (Borsani et al. 1999). Surprisingly, only a single
allele of patient 11 shares the common haplotype carried
in homozygosity by the four other patients (Lauteala et
al. 1998). This diversity might be explained by an in-
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Table 4
Mutations and Polymorphism of the SLC7A7 Gene
Mutationa Sequence Alteration Effect on Coding Sequence
Missense:
M1L ArC at 242 in exon 2 Met1Leu substitution
L334Rb TrG at 1287 in exon 7 Leu334Arg substitution
S386R CrA at 1399 in exon 8 Ser386Arg substitution
Nonsense:
W242X GrA at 967 in exon 4 Termination at codon 77
Insertion or deletion:
786insT Insertion of a T between 786 and 787 in exon 3 Frameshift after Leu182, termination at codon 190
1625insATCA Insertion of ATCA between 1625 and 1626 in exon 9 Frameshift after Ile461, termination at codon 467
197-740delc Deletion of intron 1 and exon 2 Deletion of first 168 codons
455delCTCT Deletion of CTCT at 455–458 in exon 2 Frameshift after Leu71, termination at codon 167
1291delCTTTb Deletion of CTTT at 1291–1294 in exon 7 Frameshift after Leu334, termination at codon 348
1425delTTCT Deletion of TTCT at 1425–1428 in exon 8 Frameshift after Leu395, termination at codon 516
Splicing:
IVS3 1GrA GTrAT in donor of intron 3 No mRNA studies
IVS5-2ArTd AGrTG in acceptor of intron 5 Frameshift after Val298, termination at codon 307
IVS6 1GrT GTrTT in donor of intron 6 No mRNA studies
Polymorphism:
S53S ArG at 400 in exon 2 No effect
a Mutation nomenclature according to Antonarakis (1998).
b As reported by Torrents et al. (1999).
c Previously reported as 197D543 mutation by Borsani et al. (1999).
d Previously reported as 1136-2ArT mutation by Borsani et al. (1999).
dependent mutational event on the chromosome car-
rying the different haplotype. However, the consanguin-
ity of the parents of patient 11 and the geographic origin
in common with the other four patients might favor the
hypothesis of multiple recombinational events between
the LPI locus and the markers. Similarly, the Finnish
founder mutation was also found in a single patient
without the common 6-4 haplotype (Torrents et al.
1999).
The present results indicate that, at least in Italy, LPI
is caused by several independent mutational events, a
fact that seems unusual for a rare disease. In particular,
we found three different mutations (967GrA,
1625insATCA, 197-740del) in a small geographic area
(places of patients’ origin are !50 km apart). This recalls
the so-called “reunion paradox” and another similar
phenomenon observed in Galilee (Beckmann 1996; Zlo-
togora et al. 1996). Two different genetic mechanisms
were postulated to explain the occurrence of different
mutations in a genetic isolate. The first one relies on a
digenic model, the second on both a high mutation rate
and a selective advantage for the carriers. In our case,
we do not have data supporting either of these hypoth-
eses. Only a mini-founder effect can be considered for
1625insATCA in Campania. Indeed, “private” or rare
mutations were frequently detected in Italy for other
inherited metabolic disorders, such as phenylketonuria
(Guzzetta et al. 1997), aldolase B deficiency (Santamaria
et al. 1996b), and homocystinuria caused by cystahion-
ine b-synthase deficiency (Sebastio et al. 1995). In con-
trast, a single mutation accounts for most of the Finnish
LPI alleles, in agreement with the concept of “the Finnish
disease heritage” (Norio et al. 1973).
Relationship between the Mutations and Clinical
Features
We failed to establish a genotype/phenotype correla-
tion. In fact, both intrafamilial and interfamilial phe-
notypic variability were observed in homozygotes for
the same mutation. Both the age at onset and the com-
pliance to the treatment do not seem to explain the dif-
ferences in the clinical presentation. Patients affected by
the 1625insATCA mutation present variable pheno-
types: very mild in patient 12; very mild in patient 13,
in contrast to the affected brother who died from a sud-
den hyperammonemic coma; severe in patient 14C with
additional findings such as short stature, renal insuffi-
ciency, and recurrent pancreatitis; severe in patient 15C,
a double first-cousin once removed from patient 14C,
affected by early onset of pulmonary insufficiency caused
by alveolar proteinosis; and very mild in patient 11.
Moreover, in patient 16, a 28-year-old man, homozy-
gosity for the 197-740del mutation, which removes 168
codons at the protein level, allows the mildest phenotype
we have ever observed. In contrast, his affected brother
died from a severe clinical course with a fatal hyper-
ammonemic coma, at age 6 years.
All patients, except the Japanese patient, were shown
to be homozygous for a specific mutation. This indicates
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Figure 1 Localization of all mutations of the SLC7A7 gene iden-
tified to date. The asterisk (*) indicates that the nomenclature of these
mutations is as reported by Torrents et al. (1999).
that consanguinity, observed in 5 of the 11 families, is
often associated with LPI and may explain the rare oc-
currence of the disease.
Until now, molecular analysis of patients with LPI has
only identified mutations in the SLC7A7 gene (table 4
and fig. 1). Mutations of 4F2hc, the heavy chain of the
heterodimer 4F2hc/SLC7A7, were never found, at least
in Italian patients (data unpublished). This is in agree-
ment with previous linkage studies that assigned the LPI
locus to chromosome 14q11.2 for Finnish, Italian, Swed-
ish, Latvian, Moroccan, Saudi-Arabian, and Turkish
patients (Lauteala et al. 1998). Another transcript,
SLC7A8, maps to the same chromosomal region and is
located in the same YAC 806b10 as SLC7A7 (Bassi et
al. [in press]). SLC7A8 shares a high level of homology
with SLC7A7, its pattern of expression is compatible
with the LPI pathophysiology, and the predicted protein
displays 12 TM domains. By direct sequencing of
SLC7A8, we did not find disease-causing mutations in
Italian and Finnish patients (Borsani et al. 1999). There-
fore, genetic homogeneity of LPI is definitely established.
The DNA-based tests are now easily accessible for
molecular diagnosis, genetic counseling, and prenatal di-
agnosis of LPI (Sperandeo et al. 1999). Finally, expres-
sion studies will help address questions about the effects
of some mutations, for example, S386R, and will shed
light on the functioning of the 4F2hc/SLC7A7 complex.
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